

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

PROPOSED SPIN-OFF AND LISTING OF SICHUAN RUIJIAN MEDICAL

THE PROPOSED SPIN-OFF

The Board is pleased to announce that the Company is considering the proposed spin-off of its non-wholly owned subsidiary, Sichuan Ruijian Medical, by way of a separate quotation on NEEQS without issuance of new shares (the “**NEEQS Quotation**”) and a subsequent listing on Beijing Stock Exchange subject to the then market conditions and its strategic development needs (the “**Subsequent Listing**”, together with the NEEQS Quotation, collectively as the “**Proposed Spin-off**”).

The Company has submitted an application in relation to the Proposed Spin-off to the Stock Exchange for approval pursuant to PN15. As of the date of this announcement, the Stock Exchange has confirmed that the Company may proceed with the Proposed Spin-off under PN15 of the Listing Rules. Further, the Company has also applied for, and the Stock Exchange has granted, a waiver from compliance with the assured entitlement requirement under Paragraph 3(f) of Practice Note 15 of the Listing Rules.

Sichuan Ruijian Medical intends to submit the application for its quotation on NEEQS in the second quarter of 2024, subject to the then market condition.

The Company expects that the NEEQS Quotation will not involve any issue of new shares of Sichuan Ruijian Medical and the Subsequent Listing will involve the issue of new shares of Sichuan Ruijian Medical, subject to the approval from relevant authorities, including the CSRC and Beijing Stock Exchange and the approval of the Shareholders (if required under the Listing Rules). It is intended that Sichuan Ruijian Medical will remain as a subsidiary of the Company after completion of the Proposed Spin-off, subject to the Company and its auditor’s assessment under HKFRS.

The Board believes that the Proposed Spin-off is fair and reasonable and in the interests of the Company and its shareholders as a whole as:

- (1) there is a great potential for blood purification medical device in the PRC market in terms of both market size and growth prospect. The Proposed Spin-off is expected to promote the reputation and profile of Sichuan Ruijian Medical in the PRC market and enhance its ability and opportunities to capture and benefit from such market growth, with a potential increase in sales and market share. With the reputation and profile being raised, Sichuan Ruijian Medical is expected to have more opportunities to win certain tendering, attract human resources and obtain government subsidies;
- (2) the Proposed Spin-off is also expected to allow Sichuan Ruijian Medical Group to create a clearly defined business focus, which would help further reinforce its leading position in the blood purification industry with its own integrated R&D, manufacturing, sales and services;
- (3) the Proposed Spin-off will unlock embedded value for the shareholders and help identify and establish the fair value of the Company's blood purification medical device business, in particular, the fair value represented by Sichuan Ruijian Medical Group's profitability and technology in the area of blood purification medical device;
- (4) the Proposed Spin-off will enable Sichuan Ruijian Medical to have direct access to the domestic capital market, broaden its financing channels and increase its financing capabilities; and
- (5) the Proposed Spin-off will provide the market with great clarity on the business and financial position of Sichuan Ruijian Medical and help enhance its own corporate governance.

INFORMATION ON THE COMPANY AND SICHUAN RUIJIAN MEDICAL

The Company is a leading medical device company in China and the members of the Group are principally engaged in the R&D, manufacturing and sales of (i) advanced infusion set, intravenous cannula products, insulin needles etc., (ii) blood purification medical devices, and (iii) animal-derived regenerative medical biomaterials and human tissue repair alternative products in the PRC.

Sichuan Ruijian Medical is a non-wholly owned subsidiary of the Company as of the date of this announcement. It is a joint stock company with limited liability established in the PRC on August 6,

2013. Sichuan Ruijian Medical is a medical device company, principally engaged in the R&D, manufacturing and sales of medical device for blood purification. As of the date of this announcement, the shareholding structure of Sichuan Ruijian Medical is set out below:

Shareholders of Sichuan Ruijian Medical	Shareholding Percentage
Medcore Investment ^(Note 1)	48.49%
Lepu Medical	17.11%
Shenzhen Venture Capital Manufacturing Transformation and Upgrading New Materials Fund (Limited Partnership) (深創投製造業轉型升級新材料基金(有限合夥))	10.05%
Shanghai Junwei Investment Management Center (Limited Partnership) (上海鈞衛投資管理中心(有限合夥))	8.74%
Rizhao Chengrui Corporate Management Partnership (Limited Partnership) (日照成睿企業管理合夥企業(有限合夥))	3.25%
Suzhou Industrial Park Xinjianyuan Phase IV Equity Investment Partnership (Limited Partnership) (蘇州工業園區新建元四期股權投資合夥企業(有限合夥))	2.44%
Ningbo Zhengyao Investment Management Center (Limited Partnership) (寧波正壹投資管理中心(有限合夥)) (“ Ningbo Zhengyao ”) ^(Note 2)	2.06%
Wang Tao (王滔)	1.57%
Hubei Jiuzhou Zhiyi Equity Investment Fund Partnership (Limited Partnership) (湖北九州智醫股權投資基金合夥企業(有限合夥))	1.10%
Huizhi Industrial Investment Kanglan Venture Capital (Huzhou) Partnership (Limited Partnership) (匯智產投康嵐創業投資(湖州)合夥企業(有限合夥))	1.10%
Tianjin Tongchen Medical Technology Partnership (Limited Partnership) (天津同辰醫療科技合夥企業(有限合夥))	0.97%
Ningbo Yihui Investment Management Center (Limited Partnership) (寧波醫惠投資管理中心(有限合夥))	0.92%
Tianjin Jinyitongda Venture Capital Fund Partnership (Limited Partnership) (天津金意通達創業投資基金合夥企業(有限合夥))	0.73%
Nanjing Bangsheng Yingxin No. 2 Venture Capital Partnership (Limited Partnership) (南京邦盛贏新二號創業投資合夥企業(有限合夥))	0.73%
Shanghai Panjinhua Business Consulting Partnership (Limited Partnership) (上海磐錦華商務諮詢合夥企業(有限合夥))	0.44%
Wuhan Junzheng Jiaming Venture Capital Fund Partnership (Limited Partnership) (武漢市君正佳明創業投資基金合夥企業(有限合夥))	0.18%
Suzhou Yuanrui Venture Capital Partnership (Limited Partnership) (蘇州元瑞創業投資合夥企業(有限合夥))	0.12%
Total	100%

Notes:

1. On December 22, 2023, Medcore Investment and Ningbo Zhengyao entered into an acting-in-concert agreement pursuant to which Medcore Investment and Ningbo Zhengyao agreed to exercise their voting rights unanimously in respect of their respective equity interest in Sichuan Ruijian Medical at all shareholders' meetings of Sichuan Ruijian Medical. Please refer to the announcement of the Company dated December 22, 2023.
2. Ningbo Zhengyao is the employee shareholding platform for the purpose of the stock incentive plan of Sichuan Ruijian Medical. As Sichuan Ruijian Medical does not constitute a principal subsidiary of the Company under Rule 17.14 of the Listing Rules as of the date of the announcement, the stock incentive plan of Sichuan Ruijian Medical is not subject to Chapter 17 of the Listing Rules.

LISTING RULES IMPLICATION

The Company has submitted an application in relation to the Proposed Spin-off to the Stock Exchange for approval pursuant to PN15. As of the date of this announcement, the Stock Exchange has confirmed that the Company may proceed with the Proposed Spin-off under PN15 of the Listing Rules.

As the NEEQS Quotation does not involve any issuance of new shares of Sichuan Ruijian Medical, the NEEQS Quotation does not constitute a transaction under Chapter 14 of the Listing Rules. The Company will publish announcement to update its shareholders of the progress of the NEEQS Quotation. The Subsequent Listing, if materialized, may constitute a deemed disposal and a notifiable transaction of the Company under Chapter 14 of the Listing Rules. The Company will comply with the relevant announcement and/or shareholders' approval requirements (if applicable) where appropriate. Further announcement(s) will be made by the Company in accordance with the Listing Rules as and when appropriate.

WAIVER FROM COMPLIANCE WITH THE ASSURED ENTITLEMENT REQUIREMENT UNDER PARAGRAPH 3(F) OF PN15

Paragraph 3(f) of Practice Note 15 of the Listing Rules requires a listed company carrying out a spin-off to have due regard to the interests of its existing shareholders by providing them with an assured entitlement to shares in the spun-off entity, either by way of a distribution in specie of existing shares in the spun-off entity or by way of preferred application in any offering of existing or new shares in the spun-off entity.

After due and careful consideration of the Proposed Spin-off and having taken into account the advice from the Company's PRC legal counsel, the Board has resolved not to provide assured entitlement to the Shareholders under the Proposed Spin-off due to the legal restriction in offering PRC listed shares to foreign investors.

As such, the Company has applied for, and the Stock Exchange has agreed to grant, a waiver (the "**Waiver**") from strict compliance with this requirement of Paragraph 3(f) of PN15 subject to the condition that the Company would publish an announcement stating (i) the reasons for not providing assured entitlement to the Shareholders; (ii) the legal restrictions under the PRC laws and regulations in

providing assured entitlements; and (iii) the Board's confirmation to the Company that the Proposed Spin-off and the Waiver are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

An announcement pursuant to PN15 and further announcement(s) will be made by the Company as and when appropriate in respect of the details of and any material development in relation to the Proposed Spin-Off.

Shareholders and potential investors should note that the Proposed Spin-off is subject to, among other things, the prevailing market conditions and approvals from relevant authorities, including the NEEQS, the CSRC and Beijing Stock Exchange. Accordingly, Shareholders and potential investors should be aware that the Company does not guarantee that the Proposed Spin-off will materialize, nor the timing thereof. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings when used herein:

“Board”	the board of Directors
“Company”	PW Medtech Group Limited (普华和顺集团公司), an exempted company incorporated under the laws of the Cayman Islands with limited liability on May 13, 2011
“CSRC”	China Securities Regulatory Commission
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries from time to time
“HKFRS”	Hong Kong Financial Reporting Standard
“Hong Kong”	The Hong Kong Special Administrative Region of the PRC
“Lepu Medical”	Lepu Medical Technology (Beijing) Co., Ltd. (乐普(北京)医疗器械股份有限公司), a joint stock company incorporated in the PRC on June 11, 1999 and listed on the Shenzhen Stock Exchange (stock code: 300003)
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)

“Medcore Investment”	Medcore Investment Limited (美宜科投資有限公司), a limited company incorporated under the laws of Hong Kong on September 9, 2021 and a wholly-owned subsidiary of the Company
“NEEQS”	National Equities Exchange and Quotations System
“PN15”	Practice Note 15 of the Listing Rules
“PRC”	The People’s Republic of China, which expression for the purpose of this announcement, except where the context requires otherwise, does not include Hong Kong, the Macau Special Administrative Region and Taiwan
“R&D”	research and development
“Share(s)”	ordinary share(s) of par value US\$0.0001 each in the equity interest of the Company
“Shareholder(s)”	shareholder(s) of the Company
“Sichuan Ruijian Medical”	Sichuan Ruijian Medical Technology Co. Ltd. (四川睿健醫療科技股份有限公司), a joint stock limited liability company established in PRC on August 6, 2013, a non-wholly owned subsidiary of the Company
“Sichuan Ruijian Medical Group”	Sichuan Ruijian Medical and its subsidiaries
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it in the Listing Rules
“%”	per cent

By Order of the Board
PW Medtech Group Limited
 普华和顺集团公司
Yue’e Zhang
Chairman & Chief Executive Officer

Hong Kong, May 20, 2024

As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue’e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.